| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:BMS-986020 sodium
CAS:1380650-53-2
Purity:>=95% Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
ChemeGen(Shanghai) Biotechnology Co.,Ltd.
|
| Tel: |
18818260767 |
| Email: |
sales@chemegen.com |
| Products Intro: |
Product Name:BMS-986020 sodium
CAS:1380650-53-2
Purity:98% Package:10 mg;50 mg;100 mg;500 mg;1 g;5 g;10 g
|
BMS-986020 sodium manufacturers
- BMS-986020 sodium
-
- $0.00 / 1removed
-
2025-10-24
- CAS:1380650-53-2
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | BMS-986020 sodium Basic information |
| | BMS-986020 sodium Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO: 150 mg/mL (297.32 mM); Water: < 0.1 mg/mL (insoluble) | | form | Solid | | color | Light yellow to yellow |
| | BMS-986020 sodium Usage And Synthesis |
| Description | BMS-986020 sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist[1].BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively[2]. BMS-986020 sodium is used for the treatment of idiopathic pulmonary fibrosis (IPF)[3]. | | Uses | BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist[1]. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC50s of 4.8 μM, 6.2 μM, and 7.5 μM for BSEP, MRP4, and MDR3, respectively[2]. BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF)[3]. | | References | [1]. Kihara Y, et al. Lysophospholipid receptors in drug discovery. Exp Cell Res. 2015 May 1;333(2):171-7.
[2]. Glenn Rosen, et al. LPA1 antagonists BMS-986020 and BMS-986234 for idiopathic pulmonary fibrosis: Preclinical evaluation of hepatobiliary homeostasis. European Respiratory Journal.
[3]. Palmer SM, et al. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018 Nov;154(5):1061-1069. |
| | BMS-986020 sodium Preparation Products And Raw materials |
|